FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Control arm overperformance in phase 3 oncology clinical trials. PMID 41653086 · Cancer · 2026-Feb-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial. PMID 41137194 · Int J Cancer · 2026-Feb-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Is Clinical Remission, an Ambitious Treatment Goal, Achievable in Patients with Moderate-to-Severe Asthma on Inhaled Therapies: How Ambitious Should We Be? PMID 41753185 · J Clin Med · 2026-Feb-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of a novel sodium picosulfate oral tablet in a randomized controlled trial for bowel preparation. PMID 41695285 · World J Gastroenterol · 2026-Feb-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Proton versus photon radiotherapy in adults with primary brain tumors evaluating functional survival: a phase 3 randomized controlled trial study protocol (PRIDE). PMID 41689093 · Radiat Oncol · 2026-Feb-14 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Antibiotic treatment for 1 day versus 4-7 days in patients with acute cholangitis after adequate endoscopic biliary drainage (COBRA): study protocol for a randomized controlled trial. PMID 41689066 · Trials · 2026-Feb-14 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial. PMID 41628627 · Lancet · 2026-Feb-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical Hypothyroidism After Proton Versus Photon Regional Nodal Irradiation: A Prospective Correlative Study Within the RADCOMP Randomized Trial. PMID 41692352 · Int J Radiat Oncol Biol Phys · 2026-Feb-13 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Extended window of relapse recovery in RRMS: an analysis of the DECIDE dataset. PMID 41072954 · J Neurol Neurosurg Psychiatry · 2026-Feb-13 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT. PMID 41836917 · Breast Care (Basel) · 2026-Feb-12 The record describes a retrospective subgroup analysis of the WSG-ADAPT-HR+/HER2- trial, which is not explicitly identified as a Phase III or Phase II/III trial for the drug intervention in question. The analysis integrates recurrence score and endocrine responsiveness to refine risk assessment, projecting theoretical benefit from other trials (NATALEE, monarchE) rather than reporting primary results of a randomized drug intervention comparison. While the parent trial may be randomized and involve drugs, this specific report is a secondary subgroup analysis, not a primary or definitive result report of the trial's drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of self-abdominal massage on gastrointestinal function in postoperative ileus: a randomised controlled trial protocol. PMID 41688115 · BMJ Open · 2026-Feb-12 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A randomised trial of a bioreactor-produced EV-A71 vaccine for endemic control in children. PMID 41680199 · NPJ Vaccines · 2026-Feb-12 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Fibrin sealant for prophylaxis of cervical anastomotic leakage after McKeown esophagectomy for esophageal or esophagogastric junction cancer (PLACE030): a Phase III multicenter randomized clinical trial. PMID 41677267 · Int J Surg · 2026-Feb-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the Phase 3 GRAVITI study. PMID 41674029 · Intest Res · 2026-Feb-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium. PMID 41347825 · Blood · 2026-Feb-12 The record describes a secondary prognostic study on time-to-relapse in T-cell lymphoma, using data from cohorts that include a randomized trial, but it is not the original formal-result report of a Phase III or II/III randomized trial of a drug intervention. The trial phase is not explicitly confirmed as Phase III/II in the metadata or abstract, and the report type is a secondary analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial. PMID 41211929 · N Engl J Med · 2026-Feb-12 The study is a Phase 3 randomized trial of a drug (sibeprenlimab) in IgA nephropathy, a non-oncologic condition. The primary endpoint is a change in urinary protein-to-creatinine ratio at 9 months, which is a surrogate biomarker/proteinuria outcome, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the core eligibility criteria for the oncology Kaplan-Meier digitization cohort. |
H
L
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. PMID 41196369 · N Engl J Med · 2026-Feb-12 The study is a Phase III randomized controlled trial of a drug (atacicept) with results, but it is not an oncology study; it focuses on IgA nephropathy. Therefore, it does not meet the primary eligibility criterion of being for human malignant neoplasm. |
H
L
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia. PMID 41060318 · Blood · 2026-Feb-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Memantine to preserve memory and neurocognition following craniospinal irradiation (MEMENTO): a phase 3 randomized controlled trial. PMID 41673604 · BMC Cancer · 2026-Feb-11 This is a protocol for a Phase III randomized controlled trial evaluating memantine in patients receiving craniospinal irradiation for brain tumors. While it meets criteria for oncology, human subjects, randomization, Phase III, and drug intervention, it does not present original results with a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The abstract explicitly describes the trial design and planned endpoints but reports no efficacy outcomes. The publication type includes 'Clinical Trial, Phase III' and 'Randomized Controlled Trial,' but the content is a protocol registration, not a results report. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells. PMID 41673235 · Sci Rep · 2026-Feb-11 The record describes a preclinical study in cell lines comparing different radiosensitizing approaches. While it mentions a Phase 3 trial (TrilynX), the study itself is not a report of that trial's results. It is a laboratory investigation, not a clinical trial result report, and does not present a time-to-event efficacy endpoint (OS, PFS, etc.) from a human trial. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study. PMID 41670439 · Arthritis Rheumatol · 2026-Feb-11 The study is a Phase 3 randomized, placebo-controlled trial of guselkumab (a drug intervention) in human patients with psoriatic arthritis. However, it is not an oncology study (psoriatic arthritis is a rheumatologic condition), and the reported efficacy endpoints are clinical response measures (ACR20, PASI90, etc.), not time-to-event outcomes (e.g., OS, PFS, DFS, EFS, RFS, TTP) analyzed via Kaplan-Meier or hazard ratios. Therefore, it does not meet the oncology or time-to-event criteria for inclusion. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quadruple vs triple therapy for resistant hypertension: the QUADRO trial. PMID 41667119 · Eur Heart J · 2026-Feb-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Advances in Immunotherapy for Breast Cancer. PMID 41701864 · Oncology (Williston Park) · 2026-Feb-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide. PMID 41672869 · Eur Urol · 2026-Feb-10 The record describes a multicenter randomized trial with a primary time-to-event endpoint (PSA-PFS) and drug intervention, meeting all eligibility criteria. The phase is explicitly stated as a randomized trial without a specific phase label, but given the definitive design (comparing established treatments), it qualifies as a Phase III/definitive trial. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A). PMID 41668051 · BMC Cancer · 2026-Feb-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial. PMID 41667463 · Nat Commun · 2026-Feb-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 4 Panel · risk unclear |
| Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial. PMID 41667193 · BMJ · 2026-Feb-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 4 Panel · risk unclear |
| Predictors of Efficacy Maintenance After Vunakizumab Discontinuation in Patients With Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of a Randomized Controlled Trial. PMID 41665599 · Int J Dermatol · 2026-Feb-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study. PMID 41505697 · J Clin Oncol · 2026-Feb-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 4 Figure · 5 Panel · risk unclear |
| Spinal Manipulation and Clinician-Supported Biopsychosocial Self-Management for Acute Back Pain: The PACBACK Randomized Clinical Trial. PMID 41460638 · JAMA · 2026-Feb-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Targeted Oxygen for Initial Resuscitation of Preterm Infants: The TORPIDO 30/60 Randomized Clinical Trial. PMID 41369162 · JAMA · 2026-Feb-10 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. PMID 41143759 · J Am Coll Cardiol · 2026-Feb-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| FLT3-ITD measurable residual disease from the QuANTUM-First trial. PMID 41052406 · Blood Adv · 2026-Feb-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Role of melatonin for prevention of necrotizing enterocolitis in preterm infants: a randomized controlled trial. PMID 41847903 · J Trop Pediatr · 2026-Feb-09 The study is a randomized controlled trial in humans with a drug intervention (melatonin) and reports original results, but it is not an oncology study. It focuses on a neonatal condition (necrotizing enterocolitis), which is outside the scope of the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| ESO annual stroke evidence update 2025. PMID 41706824 · Eur Stroke J · 2026-Feb-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial. PMID 41349543 · Cancer Cell · 2026-Feb-09 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
B
|
旧查询独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification. PMID 40991667 · Clin Infect Dis · 2026-Feb-09 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. PMID 40694627 · Clin Infect Dis · 2026-Feb-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine. PMID 39879629 · Clin Infect Dis · 2026-Feb-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of an educational intervention model on pesticide practices among farmers: a randomized controlled trial protocol. PMID 41654733 · BMC Public Health · 2026-Feb-07 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma. PMID 41654611 · Sci Rep · 2026-Feb-07 The trial is explicitly described as a 'pilot study' and does not meet the phase requirement (Phase III/IIIb or Phase II/III). While it is randomized, has drug intervention, and reports time-to-event efficacy endpoints, the lack of definitive Phase II/III or Phase III evidence makes it ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. PMID 41654375 · Lancet · 2026-Feb-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial. PMID 41654374 · Lancet · 2026-Feb-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials. PMID 41651961 · Sci Rep · 2026-Feb-07 The record is a secondary analysis (journal article) of data from three separate Phase III trials, not the original formal report of a single randomized trial. It investigates associations between baseline cardiovascular medication use and outcomes, which is a post-hoc or secondary analysis, not the primary trial result. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of sentinel lymph node mapping with comprehensive lymphadenectomy in p53-mutated endometrial cancer: a prospective, multi-center, non-inferiority, open-label, de-escalation, randomized, controlled trial (Study Protocol - SENTIMETREP53). PMID 41796475 · Int J Gynecol Cancer · 2026-Feb-06 The record is a protocol for a planned randomized controlled trial comparing surgical techniques. It does not report results from a completed trial. Furthermore, the intervention is surgical, not drug-containing. The explicit trial phase is not stated in the provided metadata (though 'phase3_or_definitive' is null, the lack of explicit Phase III/IIIb designation and the absence of results are primary exclusions). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial. PMID 41651834 · Nat Commun · 2026-Feb-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study. PMID 41649965 · J Neuromuscul Dis · 2026-Feb-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity, safety, and lot consistency of the anthrax vaccine adsorbed, adjuvanted for post-exposure prophylaxis of anthrax in healthy adults: A phase 3, randomized, double-blind trial. PMID 41401704 · Vaccine · 2026-Feb-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. PMID 41879224 · N Engl J Med · 2026-Feb-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Does the Fissure Last Technique Really Reduce Postoperative Airleak After Lung Resection? Results From a Prospective Randomized Controlled Trial. PMID 41689184 · Interdiscip Cardiovasc Thorac Surg · 2026-Feb-05 干预为非药物单独策略,未满足药物干预要求。 |
H
L
B
|
旧查询独有 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |